CAM
ANAB icon

ClariVest Asset Management’s AnaptysBio ANAB Stock Holding History

ClariVest Asset Management’s Portfolio ANAB Stock Details ANAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-23,200
Closed -$500K – 740
2021
Q1 		$500K Buy
23,200
+5,900
+34% +$149K 0.02% 413
2020
Q4 		$372K Buy
+17,300
New +$420K 0.01% 435

Other funds holding ANAB

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

ClariVest Asset Management's ANAB Position: Q2 2021 in Review

ClariVest Asset Management sold out of AnaptysBio (ANAB) in Q2 2021, closing a stake of 23,200 shares — an estimated $500K sold.

ClariVest Asset Management first reported a position in ANAB in Q4 2020 and held it in 2 quarters. The position peaked at $500K in Q1 2021. 122 funds tracked by Wall St. Rank hold ANAB as of Q2 2021.

  • ClariVest Asset Management reported no remaining AnaptysBio position as of Q2 2021 after selling out during the quarter.
  • ClariVest Asset Management sold 23,200 AnaptysBio shares in Q2 2021, an estimated $500K.
  • ClariVest Asset Management first reported a position in AnaptysBio in Q4 2020 and held it in 2 quarters.
  • ClariVest Asset Management's AnaptysBio position peaked at $500K in Q1 2021.
  • 122 funds tracked by Wall St. Rank held AnaptysBio as of Q2 2021.

Based on ClariVest Asset Management's 13F filing for Q2 2021, filed 9 Aug 2021.